Toroso Investments LLC Cuts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Toroso Investments LLC decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 6.0% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 5,862 shares of the biopharmaceutical company’s stock after selling 371 shares during the period. Toroso Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $4,094,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the stock. BlackRock Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.6% during the fourth quarter. BlackRock Inc. now owns 9,610,871 shares of the biopharmaceutical company’s stock worth $6,069,457,000 after purchasing an additional 244,009 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2.5% during the first quarter. Vanguard Group Inc. now owns 8,360,330 shares of the biopharmaceutical company’s stock worth $5,839,023,000 after purchasing an additional 201,815 shares in the last quarter. Capital World Investors increased its stake in shares of Regeneron Pharmaceuticals by 11.8% during the first quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock worth $4,155,451,000 after purchasing an additional 626,199 shares in the last quarter. State Street Corp increased its stake in shares of Regeneron Pharmaceuticals by 6.8% during the first quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock worth $3,579,729,000 after purchasing an additional 325,645 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Regeneron Pharmaceuticals by 13.6% during the fourth quarter. Geode Capital Management LLC now owns 1,977,302 shares of the biopharmaceutical company’s stock worth $1,245,725,000 after purchasing an additional 237,090 shares in the last quarter. Hedge funds and other institutional investors own 84.92% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $697.62 on Thursday. The firm has a market cap of $76.05 billion, a PE ratio of 13.92, a price-to-earnings-growth ratio of 2.44 and a beta of 0.29. Regeneron Pharmaceuticals, Inc. has a 52-week low of $538.01 and a 52-week high of $754.67. The company has a quick ratio of 4.39, a current ratio of 5.12 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $611.98 and its two-hundred day moving average is $637.43.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $9.94 by ($0.17). The business had revenue of $2.86 billion for the quarter, compared to analyst estimates of $2.80 billion. Regeneron Pharmaceuticals had a return on equity of 36.17% and a net margin of 39.97%. Regeneron Pharmaceuticals’s quarterly revenue was down 44.4% compared to the same quarter last year. During the same quarter last year, the company earned $27.97 earnings per share. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.99 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

REGN has been the subject of a number of research reports. Morgan Stanley raised shares of Regeneron Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $625.00 to $851.00 in a research note on Friday, September 9th. Jefferies Financial Group raised shares of Regeneron Pharmaceuticals from an “underperform” rating to a “hold” rating and upped their price objective for the company from $536.00 to $675.00 in a research note on Thursday, September 8th. Argus upped their price objective on shares of Regeneron Pharmaceuticals from $680.00 to $760.00 and gave the company a “buy” rating in a research note on Tuesday, May 31st. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, July 12th. They set a “neutral” rating and a $625.00 price objective for the company. Finally, Guggenheim upped their price objective on shares of Regeneron Pharmaceuticals from $740.00 to $925.00 in a research note on Monday. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $745.95.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, EVP Plew Daniel P. Van sold 4,696 shares of the stock in a transaction that occurred on Monday, September 12th. The shares were sold at an average price of $716.38, for a total value of $3,364,120.48. Following the sale, the executive vice president now directly owns 30,578 shares of the company’s stock, valued at approximately $21,905,467.64. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In related news, Director Bonnie L. Bassler sold 609 shares of the stock in a transaction on Friday, September 9th. The shares were sold at an average price of $741.00, for a total value of $451,269.00. Following the transaction, the director now directly owns 1,082 shares of the company’s stock, valued at approximately $801,762. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Plew Daniel P. Van sold 4,696 shares of the stock in a transaction on Monday, September 12th. The shares were sold at an average price of $716.38, for a total transaction of $3,364,120.48. Following the completion of the transaction, the executive vice president now directly owns 30,578 shares in the company, valued at $21,905,467.64. The disclosure for this sale can be found here. Insiders have sold a total of 56,740 shares of company stock worth $35,478,694 in the last ninety days. 8.99% of the stock is owned by corporate insiders.

About Regeneron Pharmaceuticals

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.